FC
RYTM icon

Farringdon Capital’s Rhythm Pharmaceuticals RYTM Stock Holding History

Farringdon Capital’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,854
Closed -$384K – 574
2024
Q4 		$384K Buy
+6,854
New +$379K 0.16% 200

Other funds holding RYTM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Farringdon Capital's RYTM Position: Q1 2025 in Review

Farringdon Capital sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2025, closing a stake of 6,854 shares — an estimated $384K sold.

Farringdon Capital first reported a position in RYTM in Q4 2024 and held it in 1 quarter. The position peaked at $384K in Q4 2024. 228 funds tracked by Wall St. Rank hold RYTM as of Q1 2025.

  • Farringdon Capital reported no remaining Rhythm Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Farringdon Capital sold 6,854 Rhythm Pharmaceuticals shares in Q1 2025, an estimated $384K.
  • Farringdon Capital first reported a position in Rhythm Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Farringdon Capital's Rhythm Pharmaceuticals position peaked at $384K in Q4 2024.
  • 228 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2025.

Based on Farringdon Capital's 13F filing for Q1 2025, filed 15 May 2025.